| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VCP |
| Uniprot No | P55072 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-806aa |
| 氨基酸序列 | MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQ LFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVI SIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGD IFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNE VGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTG KTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAI IFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRP NSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVA NETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMD DFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHP DKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTM WFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRV INQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDE KSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIR ESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDN DIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDN DDDLYG |
| 预测分子量 | 116 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3-4条关于VCP(Valosin-Containing Protein)重组蛋白研究的参考文献及其摘要概括：
1. **文献名称**：Insights into the molecular architecture of the 26S proteasome
**作者**：Hanzelmann P, et al.
**摘要内容**：通过重组表达的人源VCP/p97蛋白，结合冷冻电镜技术解析了其与共因子UBXD1的复合物结构，揭示了VCP在泛素-蛋白酶体系统中的底物识别机制。
2. **文献名称**：Structural and functional insights into the p97-VCP ATPase
**作者**：Yeung HO, et al.
**摘要内容**：利用重组表达的人源VCP蛋白，结合X射线晶体学分析其ATP酶活性位点的构象变化，阐明了VCP在ERAD(内质网相关降解)中的能量依赖型底物解折叠机制。
3. **文献名称**：Conformational transitions of the AAA+ ATPase p97 during the ATPase cycle
**作者**：Tang WK, Xia D
**摘要内容**：通过重组VCP蛋白的冷冻电镜结构解析，揭示了ATP结合与水解过程中VCP六聚体的动态构象变化，为疾病相关突变的功能缺陷提供了结构基础。
4. **文献名称**：Exome sequencing reveals VCP mutations as a cause of familial ALS
**作者**：Johnson JO, et al.
**摘要内容**：在肌萎缩侧索硬化症(ALS)家系中发现VCP基因突变，通过重组突变体蛋白的生化实验证实其ATP酶活性异常，提示VCP功能障碍与神经退行性疾病的相关性。
以上文献均涉及重组VCP蛋白的表达、结构解析或功能研究，涵盖其在蛋白质稳态及疾病机制中的关键作用。
**Background of VCP Recombinant Protein**
Valosin-containing protein (VCP), also known as p97 or CDC48. is a highly conserved AAA+ (ATPases Associated with diverse cellular Activities) ATPase critical for maintaining cellular proteostasis and regulating multiple pathways, including endoplasmic reticulum-associated degradation (ERAD), autophagy, DNA repair, and membrane fusion. Structurally, VCP forms a hexameric complex comprising two ATPase domains (D1 and D2) that hydrolyze ATP to drive conformational changes, enabling it to segregate ubiquitinated substrates from cellular structures or protein complexes.
Recombinant VCP protein is engineered via genetic cloning and expression in host systems (e.g., *E. coli*, insect, or mammalian cells*) to study its biochemical and biophysical properties. Its recombinant form retains enzymatic activity and structural integrity, making it invaluable for *in vitro* assays, drug screening, and mechanistic studies. Dysregulation or mutations in VCP are linked to neurodegenerative diseases (e.g., inclusion body myopathy with Paget’s disease and frontotemporal dementia, IBMPFD) and cancer, driving interest in VCP as a therapeutic target. Recombinant VCP enables researchers to investigate disease-related mutations, screen inhibitors, and map interaction networks with cofactors (e.g., UFD1-NPL4. p47) and ubiquitin adaptors.
Additionally, recombinant VCP is used in structural biology (e.g., cryo-EM, X-ray crystallography) to resolve mechanisms of ATP-driven conformational dynamics and substrate processing. Its role in extracting misfolded proteins during ERAD has also positioned it as a key focus in developing therapies for protein aggregation disorders. By providing a pure, functional tool, recombinant VCP accelerates both basic research and translational applications in cell biology and medicine.
×
